SYN-004 (Ribaxamase), an Oral β-Lactamase, Prevented Clostridium Difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2B Clinical Trial